优化患者治疗：富含EPA营养的随机对照试验 (OPT-EPA)
通过富含EPA的营养优化患者治疗的随机对照试验
Malnutrition is a common and serious issue for people living with cancer. Many cancer patients experience weight loss, muscle weakness, and poor quality of life due to malnutrition. This can also reduce the success of cancer treatments, increase hospital visits, and add emotional distress for both patients and their loved ones.
Treating malnutrition through good nutritional care is increasingly recognised as an important part of cancer treatment. Leading experts recommend that all cancer patients be checked for signs of malnutrition and given personalised nutrition plans when necessary. While dietary counselling and oral nutritional supplements (ONS) are often used to help patients, there is still a need for better evidence to show how well these interventions work.
A key factor contributing to malnutrition in cancer patients is inflammation. Omega-3 fatty acids, (like those found in oily fish) are known for their anti-inflammatory properties. Some studies suggest that omega-3s may help cancer patients by reducing inflammation, keeping muscles strong, improving appetite, and enhancing overall well-being.
The OPT-EPA study will investigate whether a nutritional drink, called Fortimel Forticare Sensations (FFS), can improve nutritional status in patients with lung or colorectal cancer who are at risk of malnutrition. This drink is enriched with omega-3 fatty acids (Eicosapentanoic acid (EPA) and Docosahexaenoic acid (DHA)) and provides a high amount of protein and calories in a small volume, making it easier to consume, especially for patients with taste changes.
In this study, participants will be divided into two groups. The experimental group will receive dietary counselling and standard care along with FFS, the omega-3-enriched nutritional drink, while the other (control) group will receive dietary counselling and standard care, with supplements provided only if clinically necessary. Researchers will evaluate the impact on patients' nutritional status, body weight, muscle, inflammation levels, and quality of life.
Through the OPT-EPA study, researchers hope to gain clearer insights into whether omega-3-containing supplements can provide meaningful benefits for cancer patients. Ultimately, this could help improve the quality of care and outcomes for people facing cancer-related malnutrition.
研究概览
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名：Jessica Kelly
- 电话号码：+442380599247
- 邮箱：opt-epa@soton.ac.uk
研究联系人备份
- 姓名：Conni McCarthy
- 邮箱：c.mccarthy@ed.ac.uk
学习地点
-
-
-
Oslo、挪威
- 尚未招聘
- Oslo University Hospital
-
接触：
- Olav Olav
- 电话号码：+4722930000
- 邮箱：uxolaj@ous-hf.no
-
-
-
-
-
Edinburgh、英国
- 招聘中
- Edinburgh Cancer Centre
-
接触：
- Iain Phillips
- 电话号码：01315371052
- 邮箱：iain.phillips@nhs.scot
-
Gateshead、英国
- 招聘中
- Gateshead NHS Trust
-
接触：
- Kerry Waterfield
- 电话号码：01914455712
- 邮箱：kerry.waterfield@nhs.net
-
Liverpool、英国
- 招聘中
- Clatterbridge Cancer Centre
-
接触：
- Seamus Coyle
- 邮箱：seamus.coyle@nhs.net
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Participants with stage III-IV lung and/or colorectal cancer undergoing systemic anti-cancer treatment (SACT) or starting SACT within the next 4 weeks *with non-curative intent
- Participants aged 18 or older
- Participants at nutritional risk defined as a BMI <20 kg/m2 and/or over 5% weight loss in the previous 6 months**
- Participants with systemic inflammation within 28 days of screening (CRP >10 mg/dL)
- Participants with an ECOG-PS*** score of 0, 1 or 2
- Participants willing and able to give written informed consent
Exclusion Criteria:
- Participants with a recent history of tumour resection (within 12 months)
- Participants with severe renal or hepatic failure or an intolerance to any of the ingredients of the study product
- Participants who are using dietary counselling, ONS or any form of artificial feeding at the time of recruitment
- Unable to adhere to either arm of the trial and appropriate requirements
- Contraindication to ONS including a lactose intolerance
- Females who are pregnant or of childbearing potential and not using adequate contraception
学习计划
研究是如何设计的？
设计细节
- 主要用途：支持治疗
- 分配：随机化
- 介入模型：并行分配
- 屏蔽：无（打开标签）
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的：饮食指导和富含EPA的FFS（实验性ONS）及标准护理
|
An EPA-enriched experimental Oral Nutritional Supplement |
|
无干预：饮食咨询和标准护理
|
研究衡量的是什么？
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
体重 - 轻便衣物，不穿鞋
大体时间：从基线到第56天
|
从基线到第56天
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.